Equities

Camurus AB

Camurus AB

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (SEK)110.00
  • Today's Change1.00 / 0.92%
  • Shares traded40.88k
  • 1 Year change81.22%
  • Beta1.2258
Data delayed at least 15 minutes, as of Feb 17 2020 09:50 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.

  • Revenue in SEK (TTM)78.39m
  • Net income in SEK-305.16m
  • Incorporated--
  • Employees118.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hofseth Biocare ASA74.76m-83.30m2.84bn28.00--18.50--37.94-0.2657-0.26570.23820.44770.27012.0311.86---30.09-43.71-39.71-77.7819.4521.43-111.43-187.251.90-24.660.488---8.29-0.7078-414.53---19.64--
Hansa Biopharma AB3.36m-360.01m3.25bn64.00--5.78--967.34-9.00-9.000.084114.060.0042--0.2966---44.75-38.19-49.90-41.5474.2685.18-10,701.81-4,954.36----0.0178--0.178715.76-45.18--23.28--
Immunovia AB (publ)403.60k-107.56m3.35bn49.00--8.63--8,298.28-5.50-5.500.020719.740.0009--0.0498,968.89-22.72-17.94-23.63-18.78-12,728.27-5,071.06-26,650.55-13,304.19----0.0892--123.28-22.36-91.32--81.72--
Orphazyme A/S0.00-402.77m3.60bn72.00--11.33-----14.31-14.310.0011.25------0.00-------------------66.070.0407-------81.93------
Oriola Oyj18.13bn85.31m3.96bn2.82k51.592.377.530.21840.03980.03989.490.86661.766.159.37610,823.300.82872.812.799.0920.7321.510.47061.640.39923.210.502274.7010.891.32-25.93-29.67-6.14--
Calliditas Therapeutics AB138.24m-53.75m4.40bn14.00--5.43--31.81-3.60-3.604.5320.930.1809--21.5013,824,300.00-7.03---7.29-------38.88------0.00-------52.14------
Camurus AB78.39m-305.16m5.63bn118.00--12.51--71.80-6.71-6.711.718.710.15570.64383.75833,904.30-60.61---78.21--82.54---389.29--1.84-322.830.059---9.18---23.14------
BioArctic AB281.77m88.47m5.89bn42.0079.487.2260.3020.901.011.013.1411.070.2187----6,708,881.006.87--8.49--88.94--31.40------0.0273---60.53---76.82------
Recipharm AB (publ)7.21bn213.50m7.73bn5.36k49.791.728.411.072.952.95100.5185.620.56012.916.131,061,015.001.651.431.851.6849.4247.962.952.561.603.660.451955.8719.5424.57193.4911.0536.15--
Oncopeptides AB0.00-607.81m7.86bn73.00--7.88-----12.36-12.360.0017.990.00-------73.83---86.79-------------1,623.010.00-------66.03------
Data as of Feb 17 2020. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK

Institutional shareholders

18.41%Per cent of shares held by top holders
HolderShares% Held
Max Mitteregger Kapitalf�rvaltning ABas of 30 Nov 20194.27m8.27%
Fj�rde AP-fondenas of 30 Nov 20193.00m5.81%
Catella Fondf�rvaltning ABas of 30 Nov 2019976.67k1.89%
Xact Kapitalf�rvaltning ABas of 31 Dec 2019384.08k0.74%
Enter Fonder ABas of 30 Jun 2019370.56k0.72%
SEB Investment Management ABas of 30 Jun 2019208.66k0.40%
Andra AP-fondenas of 30 Jun 2019180.86k0.35%
BlackRock Fund Advisorsas of 06 Feb 202071.92k0.14%
Skandia Investment Management ABas of 31 Dec 201923.80k0.05%
Storebrand Asset Management ASas of 31 Oct 201920.32k0.04%
More ▼
Data from 31 Dec 2016 - 31 Jan 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.